Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LncRNA TAAL regulates TIE1-mediated vascular remodeling and is associated with Diabetic Retinopathy

ABSTRACT: TIE1, an endothelial receptor-tyrosine-kinase, plays a crucial role in vascular development and remodeling, including in diseases such as diabetic retinopathy (DR). However, the molecular mechanisms and regulatory interactome governing TIE1 function remain largely unknown in endothelial biology. This study was designed to identify long noncoding-RNA (lncRNA) regulators of TIE1 and to elucidate their functional roles in endothelial biology. Through integrative screening and functional assays, we discovered a novel lncRNA, TIE1-associated angiogenic lncRNA (TAAL), that modulates TIE1 function and signaling during vascular-remodeling. Further analyses revealed that dysregulation of the TAAL–TIE1-axis is associated with pathological vascular changes observed in DR, highlighting its potential relevance to disease progression.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

SUBMITTER: Lakshita Sharma

LAB HEAD: Dr. Rajender K Motiani

PROVIDER: PXD080150 | Pride | 2026-08-02

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	C_1.mzML	Mzml
	C_2.mzML	Mzml
	C_3.mzML	Mzml
	S_1.mzML	Mzml
	S_2.mzML	Mzml

Items per page:

1 - 5 of 9

Similar Datasets

Protein O-GlcNAcylation coupled to Hippo signaling drives vascular dysfunction in diabetic retinopathy [3A]

Project description:Metabolic disorder is emerging as a crucial contributor to the pathogenesis of diabetic vascular complications including diabetic retinopathy (DR), the leading cause of blindness in the working-age population. Yet, the underlying molecular mechanisms of how the disturbed metabolic homeostasis contribute to vascular dysfunction in DR remain elusive. O-GlcNAcylation modification act as a nutrient sensor particularly sensitive to ambient glucose. Here, we observed pronounced O-GlcNAc elevation in retina endothelial cells (ECs) of DR patients and mouse models. Endothelial-specific depletion or pharmacological inhibition of O-GlcNAc transferase efficiently mitigated vascular dysfunctions. Mechanistically, we found that YAP/TAZ, key effectors of the Hippo pathway, are O-GlcNAcylated in DR. We identified Thr383 as an O-GlcNAc site on YAP, which inhibits its phosphorylation at Ser397, leading to its stabilization and activation. Consequently, highly activated YAP/TAZ, promotes vascular dysfunction by inducing a pro-angiogenic and glucose metabolic transcriptional program. These findings emphasize the critical role of O-GlcNAc-Hippo axis in DR pathogenesis and suggest its unique potential as a therapeutic target.

2024-09-24 | GSE266071 | GEO

Protein O-GlcNAcylation coupled to Hippo signaling drives vascular dysfunction in diabetic retinopathy [9A]

2024-09-24 | GSE266072 | GEO

Tissue origin of endothelial cells determines immune system modulation and regulation of HIF1α-, TGFβ- and VEGF- signaling

Project description:Dysfunction of the blood retinal barriers and/or proliferation of retinal and choroidal endothelial cells are caused by late stages of diabetic retinopathy (DR) and neovascular age-related macular degeneration (nAMD). To elucidate endothelial-derived pathomechanisms in DR and nAMD, we established immortalized mouse cell lines of retinal (REC), choroidal (ChEC) and brain (BEC)endothelial cells. We compared the functional and transcriptomic state of these cells depending on their tissue origin. Intriguingly, activation of the wingless-type MMTV integration site (Wnt)/β-catenin signaling pathway restored barrier properties in BEC and REC, but increased permeability of ChEC. Transcriptome profiling showed that the immune system and pathways such as hypoxia-inducible factor (HIF) 1/2α-, transforming growth factor (TGF) β- and vascular endothelial growth factor (VEGF) were differentially regulated among endothelial cells. These findings significantly increase the understanding of the vascular biology of endothelial cells, highlighting the fact that depending on their tissue origin, their contribution to vascular pathologies such as DR or nAMD may vary.

2024-12-05 | GSE254272 | GEO

Association between lncRNAs in plasma exosomes and diabetic retinopathy

Project description:Long noncoding RNA (lncRNA) in plasma exosomes is a potential non-invasive diagnostic biomarker for diabetic retinopathy (DR). However, the changes in plasma exosomal lncRNAs and diagnostic relevance in patients with DR patients remain unclear. A case–control study with type 2 diabetes mellitus (T2DM) and patients with comorbid DR were enrolled, and their clinical information and blood samples were collected.

2022-09-06 | GSE212594 | GEO

Vitreous of proliferative diabetic retinopathy patients

Project description:We identified lncRNA expression profiles in vitreous samples between proliferative diabetic retinopathy (PDR) patients and idiopathic macular hole (IMH) patients, and between PDR patients who had received preoperative anti-vascular endothelial growth factor (anti-VEGF) therapy and PDR patients who had received surgery alone. There had been the systemic expression differences in vitreous at the microarray level from PDR patients and IMH patients, and from PDR patients after anti-VEGF treatment and untreated PDR patients.

2022-07-15 | GSE191210 | GEO

Modeling early pathophysiological phenotypes of diabetic retinopathy in a human inner blood-retinal barrier-on-a-chip

Project description:We developed a diabetic iBRB-on-a-chip that produces novel pathophysiological phenotypes and disease pathways in vitro that are representative of clinical diagnoses. Diabetic stimulation of the iBRB-on-a-chip mirrors DR features including pericyte loss, vascular regression, ghost vessels, and production of pro-inflammatory factors. We also report transcriptomic data from diabetic iBRB MVNs that may reveal novel targets, and examine pericyte-endothelial cell stabilizing strategies.

2023-12-12 | GSE228900 | GEO

System-wide vitreous proteome dissection reveals impaired sheddase activity in diabetic retinopathy

Project description:Diabetic retinopathy (DR) is a major complication of diabetes mellitus causing significant vision loss. Despite the success of anti-VEGF therapy as an effective therapy, many DR patients do not respond well to the treatment, emphasizing the involvement of other molecular players. To unveil these, we performed deep vitreous proteome profiling of patients with proliferative DR and extracted aberrated protein networks. This revealed impairment in ectodomain shedding of several transmembrane proteins playing critical roles in neurodegeneration and angiogenesis, that pointed to defects in their regulating sheddases, particularly ADAM10, which emerged as the predominant sheddase. We confirmed that ADAM10 protease activity was reduced in ocular disease models and established that activation of ADAM10 can suppress endothelial cell activation and angiogenesis. Furthermore, we identified impaired ADAM10-AXL axis as a retinal angiogenic driver. Taken together, we demonstrate restoration of aberrant ectodomain shedding as an effective strategy for treating DR and propose ADAM10 as an attractive novel target.

2022-10-14 | PXD036033 | Pride

CX3CR1-Fractalkine Dysregulation Affects Retinal GFAP Expression, Inflammatory Gene Induction, and LPS Response in a Mouse Model of Hypoxic Retinopathy

Project description:Diabetic retinopathy (DR) causes vision loss due to sustained inflammation and vascular dam-age. The vascular damage is characterized fibrinogen leakage, angiogenesis, and hypoxia exac-erbating retinal damage. Neuronal regulation of microglia via the CX3CL1 (FKN)-CX3CR1 pathway also play a significant role in retinal pathology; here defects in the FKN-CX3CR1 pathway exacerbate inflammation, vascular damage and vision impairment. However, the con-tribution of hypoxic astrocytes to the pathological process of DR is unclear.

2025-02-17 | GSE276207 | GEO

Extracellular vesicles of human diabetic retinopathy retinal tissue and urine of diabetic retinopathy patients analyzed using mass spectrometry

Project description:Diabetic Retinopathy (DR) is a potentially blinding retinal disorder which develops through the pathogenesis of diabetes. Extracellular Vesicles (EVs) provide a novel biomarker for pre-symptomatic disease diagnosis and prognosis. Proteomic analysis was performed on explanted DR retinal tissue, DR retinal EVs and DR urinary EVs. DR samples were compared to normal retinal tissue, retinal EVs and urinary EVs, respectively

2022-12-31 | PXD034626 | Pride

Interfering VE-cadherin Y685 Phosphorylation inhibits development of experimental diabetic and prediabetic retinopathy

Project description:Diabetic retinopathy involves early retinal vascular barrier breakdown and pericyte loss, yet the initiating molecular events remain poorly defined. Vascular endothelial cadherin (VE-cadherin), a key regulator of endothelial integrity, is notably reduced in diabetic and prediabetic nucleoside diphosphate kinase B (NDPKB) deficient mouse retinas, particularly in the retinal deep capillary layer, and this decline precedes pericyte loss. In vitro, high glucose (HG) and NDPKB deficiency induced VE-cadherin Y685 phosphorylation, promoting its junctional internalization, activating the hexosamine biosynthesis pathway, and increasing angiopoietin 2 (Ang2), resulting in impaired endothelial barrier function and disrupting pericyte attachment. Preventing Y685 phosphorylation through VE-cadherin Y685F mutation blocked these HG- and NDPKB-driven pathological effects. Pharmacological intervention identified protein O-linked β-N-acetylglucosamin (O-GlcNAc) modification as a mediator of Y685-dependent Ang2 upregulation. In vivo, VE-cadherin Y685F knock-in mice were protected from diabetes- and prediabetes-induced vascular hyperpermeability, exhibited reduced protein O-GlcNAcylation and Ang2 induction, and maintained neuronal function. O-GlcNAc-enriched retinal proteomics further showed that the Y685F mutation restored balanced neurovascular and mitochondrial pathways. These findings highlight the potential of targeting VE-cadherin Y685 phosphorylation as a promising therapeutic approach to maintain retinal vascular integrity and attenuate pathological progression of diabetic and prediabetic retinopathy.

2026-03-07 | PXD072047 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data